Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the european union G5 countries: A simulation study

Clinical Therapeutics

Volumn 37, Issue 4, 2015, Pages 842-857

  Sun, Diana ^a,b   Andayani, Tri Murti ^c   Altyar, Ahmed ^a,d   Macdonald, Karen ^b   Abraham, Ivo ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b Matrix45   (United States)

^c GADJAH MADA UNIVERSITY   (Indonesia)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

biosimilar; budget impact; cost savings; febrile neutropenia; granulocyte colony stimulating factor

Indexed keywords

ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR; PEGFILGRASTIM; RECOMBINANT PROTEIN; RITUXIMAB; TRASTUZUMAB;

CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COST CONTROL; ECONOMICS; EUROPEAN UNION; HUMAN; NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COST SAVINGS; EUROPEAN UNION; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; RECOMBINANT PROTEINS; RITUXIMAB; TRASTUZUMAB;

EID: 84939986957     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.01.011     Document Type: Article

References (57)

1. European Medicines Agency. Guideline on similar biological medicinal products [EMEA/CHMP/437/04, London, 30 October 2005]. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003517.pdf.
2. European Union. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [2008]. http://ec.europa.eu/health/files/eudralex/vol-1/dir-2001-83-cons/dir2001-83-cons-20081230-en.pdf.
3. European Union. Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use [L 159/46, 27.6.2003]. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:159:0046:0094:en:PDF.
4. U.S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product [February 2012]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
5. U.S. Food and Drug Administration. Quality considerations in demonstrating biosimilarity to a reference protein product [February 2012]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf.
6. U.S. Food and Drug Administration. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009 [February 2012]. http://www.fda.gov/downloads/Drugs/Guidances/UCM273001.pdf.
7. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs) [Geneva, 19 to 23 October 2009]. http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf.
8. M. Wadhwa, H.N. Kang, and I. Knezevic WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24-26 August, 2010 Biologicals 39 2011 349 357
9. European Medicines Agency. Zarzio - filgrastim [28/08/2014]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000917/human-med-001170.jsp&mid=WC0b01ac058001d124.
10. European Medicines Agency. Summary of product characteristics - Zarzio. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000917/WC500046525.pdf. Accessed September 23, 2014.
11. European Medicines Agency. Summary of product characteristics - Tevagrastim. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000827/WC500036664.pdf. Accessed September 23, 2014.
12. European Medicines Agency. Tevagrastim - filgrastim. 2014; http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000827/human-med-001089.jsp&mid=WC0b01ac058001d124.
13. European Medicines Agency. Nivestim - filgrastim. 2014; http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001142/human-med-001344.jsp&mid=WC0b01ac058001d124.
14. European Medicines Agency. Summary of product characteristics - Nivestim. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/001142/WC500093661.pdf. Accessed September 23, 2014.
15. M.S. Aapro, J. Bohlius, and D.A. Cameron 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 2011 8 32
16. J. Crawford, C. Caserta, F. Roila Group EGW Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications Ann Oncol 21 suppl 5 2010 v248 v251
17. J. de Naurois, I. Novitzky-Basso, and M.J. Gill Management of febrile neutropenia: ESMO Clinical Practice Guidelines Ann Oncol 21 suppl 5 2010 v252 v256
18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - Myeloid growth factors [Version 2.2014]. http://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician-gls/pdf/myeloid-growth.pdf.
19. T.J. Smith, J. Khatcheressian, and G.H. Lyman 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 2006 3187 3205
20. R. Haustein, C. de Millas, A. Höer, and B. Häussler Saving money in the European healthcare systems with biosimilars GaBI Journal 1 2012 120 126
21. Walsh K. Biosimilars' utilization and the role payers do play in driving uptake in Europe: an industry perspective [Biosimilar Medicines 11th EGA International Symposium, April 2013]. http://www.sandoz-biosimilars.com/cs/www.sandoz-biosimilars.com-v3/assets/media/shared/documents/presentations/Ken Walsh EGA Annual Meeting 2013.pdf.
22. G. Dranitsaris, E. Amir, and K. Dorward Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations Drugs 71 2011 1527 1536
23. M. Aapro, P. Cornes, and I. Abraham Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia J Oncol Pharm Pract 18 2012 171 179
24. D.E. Gerber Targeted therapies: a new generation of cancer treatments Am Fam Physician 77 2008 311 319
25. M. Danova, S. Chiroli, G. Rosti, and Q.V. Doan Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients Tumori 95 2009 219 226
26. E.J. Ip, A. Lee-Ma, L.S. Troxell, and J. Chan Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide Am J Health Syst Pharm 65 2008 1552 1555
27. Z. Liu, Q.V. Doan, J. Malin, and R. Leonard The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK Appl Health Econ Health Policy 7 2009 193 205
28. D.W. Maher, G.J. Lieschke, and M. Green Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial Ann Intern Med 121 1994 492 501
29. J. Sehouli, A. Goertz, and T. Steinle [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany] Dtsch Med Wochenschr 135 2010 385 389
30. F.A. Holmes, J.A. O'Shaughnessy, and S. Vukelja Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 2002 727 731
31. M.D. Green, H. Koelbl, and J. Baselga A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 2003 29 35
32. I. Abraham, S. Tharmarajah, and K. MacDonald Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors Expert Opin Drug Saf 12 2013 235 246
33. C. Falandry, M. Campone, and G. Cartron Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines Eur J Cancer 46 2010 2389 2398
34. D. Almenar, J. Mayans, and O. Juan Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study Eur J Cancer Care (Engl) 18 2009 280 286
35. D. Weycker, J. Hackett, and J.S. Edelsberg Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40 2006 402 407
36. Lauer Fischer. http://www2.lauer-fischer.de/home/. Accessed June 11, 2013.
37. Gestion risques maladie. http://www.codage.ext.cnamts.fr/. Accessed June 11, 2013.
38. The riaque. http://www.theriaque.org/apps/recherche/rch-simple.php. Accessed June 11, 2013.
39. Codifa. http://www.codifa.it/. Accessed June 11, 2013.
40. Portalfarma. http://www.portalfarma.com/Paginas/default.aspx. Accessed June 11, 2013.
41. Pharmacy2U. https://http://www.pharmacy2u.co.uk/. Accessed September 26, 2014.
42. Oanda. http://www.oanda.com/currency/historical-rates/. Accessed June 11, 2013.
43. M. Pfreundschuh, L. Trumper, and M. Kloess Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL Blood 104 2004 634 641
44. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
45. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
46. M.R. Choi, C.A. Solid, and V.M. Chia Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy Support Care Cancer 22 2014 1619 1628
47. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
48. P. Cornes The economic pressures for biosimilar drug use in cancer medicine Targeted Oncol 7 suppl 1 2012 S57 S67
49. A. Covic, J. Cannata-Andia, and G. Cancarini Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council Nephrol Dial Transplant 23 2008 3731 3737
50. B.R. Hirsch, and G.H. Lyman Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw 9 2011 934 942 (quiz 943)
51. Association EGM. Vision 2015. The EGA's thoughts on how to improve the legal and regulatory framework for generic and biosimilar medicines [October 2010]. http://www.hup.hr/EasyEdit/UserFiles/Granske-udruge/HUP-UPL/EGA-Vision-2015.pdf.
52. H. Schellekens How similar do 'biosimilars' need to be? Nat Biotechnol 22 2004 1357 1359
53. H. Schellekens Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity Eur J Clin Invest 34 2004 797 799
54. H. Schellekens Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Discov 1 2002 457 462
55. P. Gascón, H. Tesch, and K. Verpoort Clinical experience with Zarzio(R) in Europe: what have we learned? Support Care Cancer 21 2013 2925 2932
56. H. Schellekens Biosimilar therapeutics-what do we need to consider? NDT Plus 2 Suppl 1 2009 i27 i36
57. M.S. Aapro What do prescribers think of biosimilars? Target Oncol 7 suppl 1 2012 S51 S55